A
Andrei G. Botikov
Publications - 8
Citations - 2089
Andrei G. Botikov is an academic researcher. The author has contributed to research in topics: Vaccination & Virus. The author has an hindex of 3, co-authored 6 publications receiving 1024 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,A. I. Tukhvatulin,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Sergey Zyryanov,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +30 more
TL;DR: Gam-COVID-Vac (Sputnik V) showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials as discussed by the authors.
Journal ArticleDOI
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Denis Y. Logunov,Inna V. Dolzhikova,Olga V. Zubkova,Amir I Tukhvatullin,Dmitry V. Shcheblyakov,Alina S. Dzharullaeva,Daria M. Grousova,Alina S. Erokhova,Anna V. Kovyrshina,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,Tatiana A Ozharovskaya,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,Nadezhda L. Lubenets,Daria A. Egorova,M M Shmarov,Natalia A. Nikitenko,Morozova Lf,Elena A Smolyarchuk,Evgeny V Kryukov,Vladimir F Babira,Sergei V. Borisevich,Boris S. Naroditsky,Alexander L. Gintsburg +31 more
TL;DR: The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants and was safe and well tolerated.
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
A. I. Tukhvatulin,Inna V. Dolzhikova,Dmitry V. Shcheblyakov,Olga V. Zubkova,Alina S. Dzharullaeva,Anna V. Kovyrshina,Nadezhda L. Lubenets,Daria M. Grousova,Alina S. Erokhova,Andrei G. Botikov,Fatima M. Izhaeva,Olga Popova,T A Ozharovskaia,Ilias B Esmagambetov,Irina A Favorskaya,Denis I. Zrelkin,Daria V Voronina,Dmitry N. Shcherbinin,Alexander S. Semikhin,Yana V. Simakova,Elizaveta A. Tokarskaya,M M Shmarov,Natalia A. Nikitenko,Vladimir A. Gushchin,Elena A Smolyarchuk,Tatiana G. Zubkova,Konstantin A. Zakharov,Vasiliy B. Vasilyuk,Sergei V. Borisevich,B.S. Naroditsky,Denis Y. Logunov,Alexander L. Gintsburg +31 more
TL;DR: In this paper, a single-dose vaccine based on recombinant adenovirus type 26 (rAd26) vector carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein -Sputnik Light was developed.
Patent
Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments)
Olga V. Zubkova,Ozharovskaia Tatiana Andreevna,Inna V. Dolzhikova,Olga Popova,Dmitrii Viktorovich Shchebliakov,Daria M. Grousova,Alina Shahmirovna Dzharullaeva,A. I. Tukhvatulin,N. M. Tukhvatulina,D N Shcherbinin,Esmagambetov Ilias Bulatovich,Elizaveta A. Tokarskaya,Andrei G. Botikov,Borisevich Sergei Vladimirovich,B.S. Naroditsky,Denis Yuryevich Logunov,Aleksandr Leonidovich Gintsburg +16 more
TL;DR: In this article, a method is disclosed for inducing specific immunity to the SARS-CoV-2 virus, comprising administering one or more immunobiological agents to the mammalian body for the prevention of diseases caused by the severe respiratory syndrome virus SARS CoV2.
Journal ArticleDOI
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
A. I. Tukhvatulin,Ilya Gordeychuk,Inna V. Dolzhikova,Alina S. Dzharullaeva,M. E. Krasina,Ekaterina Bayurova,Daria M. Grousova,Anna V. Kovyrshina,Alla Kondrashova,S. A. Gulyaev,T V Gulyaeva,Andrey V. Moroz,V. V. Illarionova,Ilya D. Zorkov,A. A. Iliukhina,A.Yu. Shelkov,Andrei G. Botikov,Alina S. Erokhova,Dmitry V. Shcheblyakov,Ilias B Esmagambetov,Olga V. Zubkova,Elisaveta A. Tokarskaya,Daria M. Savina,Yulia R. Vereveyko,Anastasiya S. Ungur,Boris S. Naroditsky,Aydar A. Ishmukhametov,Denis Y. Logunov,Alexander L. Gintsburg +28 more
TL;DR: It is demonstrated that the intranasally delivered Gam-COVID-Vac (Sputnik V) vaccine induced a robust (no less than 180 days) systemic and local immune response in mice and is believed to be a “silver bullet” that could bring the COVID-19 pandemic to an end.